Company News
Argenx to Acquire Forte Biosciences for $2.2B
Argenx NV agreed to acquire Dallas‑based Forte Biosciences for $2.2 billion in cash at $77 per share, a ~40% premium.
Forte shares jumped nearly 39% in pre‑market trading to $76.11, while Argenx fell
